Navigation Links
Neurocrine Biosciences Reports Third Quarter 2010 Results
Date:10/28/2010

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the quarter ended September 30, 2010.

For the third quarter of 2010, the Company reported net income of $3.3 million, or $0.06 per share, compared with a net loss of $8.2 million, or $0.21 per share, for the same period in 2009. For the nine months ended September 30, 2010, the Company reported a net loss of $10.5 million, or $0.20 per share, as compared to a net loss of $43.1 million, or $1.11 per share, for the same period last year.

The Company's balance sheet on September 30, 2010 reflected total assets of $149.9 million, including cash, investments and receivables of $140.4 million.

"The financial impact of our two recent collaboration agreements with Abbott and Boehringer Ingelheim is evident in these third quarter financial results and the cash and investments position of Neurocrine," said Timothy P. Coughlin, Chief Financial Officer of Neurocrine Biosciences. "We will continue the fiscal discipline that has been ingrained in the Company over the past three years, while advancing our lead clinical programs; elagolix, VMAT2 and Urocortin 2 and bringing new clinical candidates forward from our research and discovery platform."

Revenues for the third quarter of 2010 were $14.4 million, compared to $0.7 million for the same period in 2009. Revenues for the nine months ended September 30, 2010 were $19.8 million, compared with $2.2 million for the same period in 2009. The increase in revenue is due to our recently executed collaboration agreements with Abbott and Boehringer Ingelheim, for our GnRH (elagolix) and GPR119 programs, respectively. During the third quarter of 2010, we recognized revenue of $8.5 million from amortization of up-front license fees and $5.2 million resulting from internal and external research and d
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
2. Neurocrine Biosciences Reports First Quarter 2008 Results
3. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
4. Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis
5. Neurocrine Announces Top-Line Results From 702 Study (Lilac PETAL Study) of Elagolix for Treatment of Endometriosis Pain
6. Neurocrine Biosciences Presents Elagolix Data
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2009 Financial Results
8. Neurocrine Biosciences Reports Third Quarter 2009 Results
9. Neurocrine Advances VMAT2 Inhibitor Program
10. Neurocrine Biosciences to Present at the 21st Annual Piper Jaffray Health Care Conference
11. Neurocrine Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Parnell Pharmaceuticals ... compounds that will be added to Parnell,s already ... CIMTECH Pty Ltd, a biotechnology company. The compounds ... have shown promise in bone regeneration and dermal ... develop the compounds for the veterinary market with ...
(Date:7/24/2014)... July 24, 2014  Restore Health, a leading ... pharmaceuticals, announced that it is now offering pharmacogenetics ... each individual based upon their particular genetic makeup. ... the interaction between a patient,s genetics and their ... excited to provide this new service to healthcare ...
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5
... a next-generation oncology diagnostics company focused on improving ... closed a $21 million series A financing. ... and included Bessemer Venture Partners, Physic Ventures and ... ) , On-Q-ity is developing diagnostics to determine ...
... 3 Reportlinker.com announces that a new ... catalogue. , Wheelchair Market Shares, ... , http://www.reportlinker.com/p0157387/Wheelchair-Market-Shares-Strategies-and-Forecasts-Worldwide-2009-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... This 2009 study has 484 pages, 235 ...
Cached Medicine Technology:Cancer Diagnostics Company, On-Q-ity, Raises $21M in Series A Funding for the Development of Technologies to Personalize Cancer Therapy 2Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 2Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 3Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 4Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 5Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 6Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 7Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 8Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 9Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 10Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 11Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 12Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 13Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 14Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 15Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 16Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 17Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 18Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 19Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 20Reportlinker Adds Wheelchair Market Shares, Strategies, and Forecasts, Worldwide, 2009 to 2015 21
(Date:7/27/2014)... University scientists have shown that a powerful drug given ... only halves the early risk of rejection, but that ... drugs to be used after the operation. , The ... and presented at the World Transplant Congress in San ... difficult transplant conundrum: the powerful combinations of treatments used ...
(Date:7/27/2014)... July 27, 2014 According to a ... Devices Market (Endoscopes, Endoscopic Operative Devices, and Visualization Systems) ... Forecast, 2013-2019" the global endoscopy devices market was valued ... to grow at a CAGR of 6.8% from 2013 ... 36.9 billion in 2019. , Endoscopy procedures are performed ...
(Date:7/27/2014)... constant expansion of companies across the globe has led ... factors that have increased this demand include the application ... learning and development, security and safety, and knowledge sharing ... video market value has crossed $11.21 billion in 2013 ... with a compound annual growth rate (CAGR) of 25.97%. ...
(Date:7/27/2014)... July 27, 2014 The North American ... estimated at $1570 million in 2014, and it is ... CAGR of 4.64%. The report incorporates the factors that ... expectations of growth rates and projected total expenditure. The ... the global markets. Apart from the general overview of ...
(Date:7/27/2014)... (Sunday July 27 11:45 am ET): A ... the surgical sitehas been reduced by 77 percent ... the American College of Surgeons National Surgical Quality ... case study presented at the 2014 ACS NSQIP ... Columbia, reportedly reduced its rate of cardiac surgical ...
Breaking Medicine News(10 mins):Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 2Health News:Kidney transplant drug halves the early risk of rejection and allows less toxic treatment 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 2Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 3Health News:Global Endoscopy Devices Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019 4Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 2Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 3Health News:North America Enterprise Video Market is Expected to Reach $13.00 billion in 2018 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 2Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 3Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 4Health News:North America Security and Surveillance Radar Market is Expected to Reach $2030 million in 2019 - New Report by MicroMarket Monitor 5Health News:Surgical safety program greatly reduces surgical site infections for heart operations 2Health News:Surgical safety program greatly reduces surgical site infections for heart operations 3Health News:Surgical safety program greatly reduces surgical site infections for heart operations 4
... , PALO ALTO, Calif., Aug. 10 ... will report its second quarter 2009 financial results on Tuesday, August 11, ... to discuss the results, provide guidance for 2009, and give a company ... Time. , , The live webcast and press release ...
... Aug. 10 VION PHARMACEUTICALS, INC. (OTC Bulletin ... Oncologic Drugs Advisory Committee (ODAC) Meeting at which its lead ... , , The ODAC reviews and evaluates ... human drug products for use in the treatment of cancer ...
... 10, 2009 UT Southwestern Medical Center researchers are ... track down and kill cancer cells in patients with ... Researchers are testing a tumor-specific protein called recombinant ... interact with the body,s immune system and generate a ...
... - Researchers from Indiana University,s Center for Health Policy ... government-sponsored health insurance for individuals under age 65 remains ... described or how involved the government would be. ... a government-sponsored health insurance option, such as that being ...
... help contribute to obesity among its users, according to a ... Researchers found that the average user of food stamps had ... The link between food stamps and higher weight was almost ... BMI than those not in the program, the study found. ...
... of all human cancer tumors, the Ras protein literally "drives ... Faculty of Life Sciences at Tel Aviv University. Prof. Kloog ... anti-Ras drug against pancreatic cancer, currently in clinical trials. Now, ... Journal of Pharmacology shows that the drug might be able ...
Cached Medicine News:Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 2Health News:Vion Pharmaceuticals Announces Oncologic Drugs Advisory Committee Meeting for Onrigin(TM) 3Health News:UT Southwestern researchers launch study into search-and-destroy antigen for deadly skin cancer 2Health News:Americans remain divided on government involvement in health insurance, IU survey shows 2Health News:Americans remain divided on government involvement in health insurance, IU survey shows 3Health News:Food stamp use linked to weight gain, study finds 2Health News:Food stamp use linked to weight gain, study finds 3Health News:Taking the needle's sting out of diabetes 2
Inquire...
Inquire...
Inquire...
Inquire...
Medicine Products: